Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2017 08:01 ET | Source: Achaogen Inc.

Achaogen Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., June 22, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
June 05, 2017 08:00 ET | Source: Achaogen Inc.

Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting

-- Oral presentations highlighted data from plazomicin Phase 3 EPIC and CARE clinical trials -- -- Newly-released in vitro data demonstrated potent activity of plazomicin against contemporary...
June 01, 2017 08:00 ET | Source: Achaogen Inc.

Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate

-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing...
May 31, 2017 16:01 ET | Source: Achaogen Inc.

Achaogen Announces Closing of Public Offering

SOUTH SAN FRANCISCO, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...
May 26, 2017 08:01 ET | Source: Achaogen Inc.

Achaogen Announces Multiple Plazomicin Presentations at ASM Microbe 2017 Annual Meeting

- Two oral presentations highlighting data from plazomicin Phase 3 EPIC and CARE clinical trials - - Eleven poster presentations highlighting plazomicin’s activity against MDR Enterobacteriaceae,...
May 25, 2017 08:00 ET | Source: Achaogen Inc.

Achaogen Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...
May 23, 2017 16:07 ET | Source: Achaogen Inc.

Plazomicin Granted FDA Breakthrough Therapy Designation

SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
May 23, 2017 16:02 ET | Source: Achaogen Inc.

Achaogen Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...
May 08, 2017 16:01 ET | Source: Achaogen Inc.

Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update

-- Presented additional Phase 3 EPIC and CARE trial data highlighting the safety and efficacy of plazomicin during late-breaker session at ECCMID -- -- Plazomicin registration activities on track;...
May 05, 2017 08:01 ET | Source: Achaogen Inc.

Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria

The Bill & Melinda Gates Foundation is committing up to $20 million in grant funding and equity investment to further the development of an antibody platform and discovery of monoclonal antibody...